RWE and Patient-Centered Outcomes

Widespread availability of real-world data has enabled the generation of evidence and insights that benefit patients, providers, plans, and industry. When that evidence reflects patient outcomes, it provides an invaluable perspective on the consumer experience. Explore our real-world evidence (RWE) analyses and guidance to support your strategic decisions.

Vanessa Nyawabila

Decentralized Clinical Trials for Rare Disease Treatments

Decentralized clinical trials offer the potential to democratize rare disease research, advancing drug development and improving patient experiences.

Taylor Schwartz

Use of Patient-Centered Outcomes in ICER Assessments

Avalere assessed the current use of patient-centered outcomes in ICER evidence reports and determined the patient voice minimally influences modeling results.

Michael Ciarametaro

How Can Patients and Caregivers Participate in Negotiation?

Recently released guidance and a second draft Negotiation Data Elements ICR introduce several opportunities for patients and caregivers to shape negotiation.

Amanda Napoles

Implementation Science Integrates Evidence into Care

Despite proven benefits, evidence-based interventions are rarely adopted. Implementation science can support the integration of such interventions in routine healthcare.

Sarah Alwardt

ISPOR 2023 Presentation: The Future of Value and Evidence Strategy

Avalere’s expert presentations at ISPOR described the IRA’s impact on evidence strategy and highlighted a recent study to capture total disease burden.

Nicole Betor

What’s Next for Patient-Centered Value?

A significant push towards patient-centered value has occurred in recent years, yet a validated instrument to collect patient-centered data has not been established. The Patient Perspective Value Framework (PPVF) Initiative offers an approach for addressing this missing piece.

Elizabet Shvets

Survey Finds 58% of Payers Use Outcomes-Based Contracts

In 2022, over half of payers had at least one outcomes-based contract (OBC) and used claims-based outcomes, despite acknowledging the limitations of using claims to measure clinical benefit.

Sarah Alwardt

RWE Considerations Throughout Product Development Cycle

Drug manufacturers can use real-world evidence (RWE) before and after approval to advance product development and adoption.

Shelby Harrington

Video: The Future of Patient-Centric Value

Avalere experts Amanda Napoles and Shelby Harrington share recommendations for shifting to patient-centered value during our 2023 Outlook webinar.

Naila Wahid

Patient- and Caregiver-Centered Value in Rare Disease Treatment

Traditional health technology assessments fall short in accounting for how therapy addresses the total burden of illness experienced by affected individuals.

Shelby Harrington

Video: Patient-Centered Value Frameworks

Avalere experts will discuss patient-centric value frameworks, their utility to different stakeholders, and how they can drive the transformation to a patient-centered, equitable health system at the AMCP Nexus 2022 conference.

Patient–Provider Collaboration: Shared Decision Making in Cancer Care

In the latest installment of Avalere’s ongoing insight series about shared decision making, Michelle Bruno, Associate Principal in Avalere’s Center for Healthcare Transformation, describes the role it can play in cancer care.

Medicare Beneficiary Care Differences by Practice Ownership

Avalere released a white paper analyzing spending and utilization among Medicare beneficiaries receiving care from independent physician practices and hospital-owned physician practices in Ohio.

Alex Du Joins Avalere Health’s Market Access Practice

Avalere Health welcomes Alex (Shuang) Du as an associate principal to its Market Access practice. He will support a variety of Avalere’s clients in navigating the evolving healthcare landscape.

Massey Whorley

Majority of API in US-Consumed Medicines Is Produced in the US

Analysis of the most recent available trade data finds that 53% of API, in dollars, used in domestically consumed medicines came from the US in 2020.

Treating Depression Reduces Medicare Costs; Provider Challenges Remain

A recent Avalere analysis of Medicare Fee-for-Service (FFS) data illustrates that treating major depressive disorder (MDD) in Medicare-eligible beneficiaries results in a 4% reduction in total cost compared to untreated patients, highlighting the importance of incentivizing adequate provider supply and payment in the geriatric psychiatry market.

Sign up to receive more insights about RWE and Patient-Centered Outcomes
Please enter your email address to be notified when new RWE and Patient-Centered Outcomes insights are published.

Back To Top